Pharming Group (PHAR)
8.333
-0.19
(-2.20%)
USD |
NASDAQ |
Nov 04, 16:00
8.40
+0.07
(+0.81%)
After-Hours: 20:00
Pharming Group Enterprise Value: 488.90M for Nov. 4, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 04, 2024 | 488.90M |
| November 01, 2024 | 501.61M |
| October 31, 2024 | 528.07M |
| October 30, 2024 | 524.67M |
| October 29, 2024 | 512.46M |
| October 28, 2024 | 523.32M |
| October 25, 2024 | 513.82M |
| October 24, 2024 | 486.69M |
| October 23, 2024 | 531.46M |
| October 22, 2024 | 529.88M |
| October 21, 2024 | 528.07M |
| October 18, 2024 | 545.11M |
| October 17, 2024 | 507.71M |
| October 16, 2024 | 512.46M |
| October 15, 2024 | 513.82M |
| October 14, 2024 | 500.94M |
| October 11, 2024 | 500.25M |
| October 10, 2024 | 519.25M |
| October 09, 2024 | 510.43M |
| October 08, 2024 | 514.50M |
| October 07, 2024 | 493.47M |
| October 04, 2024 | 469.05M |
| October 03, 2024 | 497.17M |
| October 02, 2024 | 473.12M |
| October 01, 2024 | 506.36M |
| Date | Value |
|---|---|
| September 30, 2024 | 483.29M |
| September 27, 2024 | 506.08M |
| September 26, 2024 | 474.87M |
| September 25, 2024 | 452.48M |
| September 24, 2024 | 445.70M |
| September 23, 2024 | 449.64M |
| September 20, 2024 | 444.68M |
| September 19, 2024 | 475.54M |
| September 18, 2024 | 468.76M |
| September 17, 2024 | 467.06M |
| September 16, 2024 | 459.26M |
| September 13, 2024 | 438.91M |
| September 12, 2024 | 440.61M |
| September 11, 2024 | 413.14M |
| September 10, 2024 | 407.71M |
| September 09, 2024 | 404.32M |
| September 06, 2024 | 410.42M |
| September 05, 2024 | 430.09M |
| September 04, 2024 | 436.03M |
| September 03, 2024 | 445.36M |
| August 30, 2024 | 451.80M |
| August 29, 2024 | 457.91M |
| August 28, 2024 | 436.88M |
| August 27, 2024 | 480.97M |
| August 26, 2024 | 459.26M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
376.23M
Minimum
Jun 16 2022
1.027B
Maximum
Dec 23 2020
642.52M
Average
668.74M
Median
Apr 20 2023
Enterprise Value Benchmarks
| uniQure NV | -150.68M |
| ProQR Therapeutics NV | 198.19M |
| Merus NV | 2.874B |
| argenx SE | 32.06B |
| Pharvaris NV | 926.83M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -1.034M |
| Revenue (Quarterly) | 74.85M |
| Total Expenses (Quarterly) | 70.74M |
| EPS Diluted (Quarterly) | -0.02 |
| Gross Profit Margin (Quarterly) | 90.89% |
| Profit Margin (Quarterly) | -1.38% |
| Earnings Yield | -3.24% |
| Normalized Earnings Yield | -3.244 |